Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00251472
Status:
COMPLETED
Last Update Posted:
2012-05-11
First Post:
2005-11-08
Brief Title:
A Phase II Trial of Abraxane Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer
Sponsor:
Veeda Oncology
Organization:
Veeda Oncology
Study Overview
Official Title:
A Phase II Trial of Abraxane Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase II open-label non-randomized study in patients with locally advanced or metastatic breast cancer
Each cycle of treatment will be 4 weeks in length Patients will be radiologically evaluated every 8 weeks for response Patients will continue to receive study treatment until disease progression or unacceptable toxicity
Each cycle of treatment will be 4 weeks in length Patients will be radiologically evaluated every 8 weeks for response Patients will continue to receive study treatment until disease progression or unacceptable toxicity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None